Patent ID: 6693177
Filing Date: 2004-02-17
Classification: C07K

Abstract:
A novel process for preparation of O-acetyl specific immunoglobulins as a biomarker specific for O-acetylated sialic acid for diagnosing, monitoring treatment outcome and predicting relapse of acute lymphoblastic leukemia, said process comprising the steps of:(i) separating serum from whole blood from a patient suffering from acute lymphoblastic leukemia; (ii) removing galactose-binding proteins from said serum by column chromatography on an asialo-bovine submaxillary mucin affinity matrix; (iii) collecting the unbound galactose-free protein fraction from the affinity matrix; (iv) passing said galactose-free protein fraction over another affinity matrix having terminal O-acetyl sialic acid moiety to capture the O-acetyl sialic acid specific protein fraction; (v) eluting the O-acetyl sialic acid specific protein fraction with a buffer at alkaline pH in the range of about 8.0-11.0 followed by neutralization of said fraction; and (vi) purifying from the O-acetyl sialic acid specific protein fraction, the O-acetyl sialic acid specific immunoglobulins.